Lunai Bioworks

What Lunai Bioworks does

Lunai Bioworks is a publicly traded biotechnology company that has built an AI-biology integrated drug discovery platform serving major pharmaceutical partners. The company combines three proprietary platform components: Augusta, an AI/ML engine that integrates genomic, proteomic, and phenotypic data into a unified view of disease; Phenograph, a translational system that prioritizes therapeutic targets by druggability, patient stratification, and clinical feasibility; and a high-throughput in vivo modeling capability using living zebrafish combined with machine vision to validate AI-derived insights in real time. The company processes millions of phenotypic datapoints annually and applies the platform across neurology programs (KCC2/Epilepsy, Parkinson's Disease, Alcohol Use Disorder), oncology, and a newer biodefense program covering real-time neurotoxicity assessment.

The company's commercial model is structured as enterprise R&D collaborations with large pharmaceutical partners rather than product sales. Named partners include Pfizer, Janssen, Merck, Supernus, and Cure, engaged across biomarker discovery, target identification and validation, and neurology-focused compound development. Revenue is currently zero with a negative EPS of -$7.55, and the stock is classified as distressed, reflecting a pre-commercial stage. Recent corporate activity has been capital-intensive: two preferred equity rounds totaling $40M in March and May 2026 funded the acquisition of blood-brain barrier delivery technology from Clemann Group, SAS, and additional IP assets including a prodrug system and nose-to-brain delivery pathway. Earlier rounds include a $106.8M raise in February 2024 and the acquisition of BioSymetrics in February 2025. The company operates from Sacramento, California, with additional presence in the Netherlands, and is led by CEO David Weinstein with Rene Sindlev as co-founder and Chairman.

Name

Lunai Bioworks

Legal name

Lunai Bioworks, Inc.

Website

https://renovarogroup.com

Company type

Public

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Lunai Bioworks is a publicly traded biotech that operates an AI-biology integrated drug discovery platform (Augusta AI/ML engine, Phenograph translational system, and zebrafish in vivo modeling with machine vision), serving large pharmaceutical partners including Pfizer, Janssen, Merck, Supernus, and Cure through R&D collaborations across neurology, oncology, and biodefense.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Phenomics platform
• CNS drug development
• Biomarker discovery
• Target identification

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical R&D Collaborations: Lunai Bioworks generates revenue through strategic R&D collaborations with pharmaceutical partners. The company currently shows zero revenue and negative EPS of -$7.55, indicating a pre-commercial stage focused on pipeline development and partnerships rather than immediate revenue generation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Lunai Bioworks operates an integrated AI-biology drug discovery platform that combines an AI/ML engine (Augusta), a translational prioritization system (Phenograph), and high-throughput in vivo zebrafish modeling with machine vision. It monetizes this platform through R&D collaborations with large pharmaceutical companies for biomarker discovery, target identification, and validation across oncology, neurology, and biodefense programs. The company has also acquired a blood-brain barrier (BBB) delivery platform to enable CNS therapeutics.

Product overview

Lunai Bioworks is a biotechnology company operating a unified AI-biology integration platform consisting of three core components: Augusta (AI/ML Engine for disease signature identification across genomic, proteomic, and phenotypic data), Phenograph (Translational System for target prioritization and therapeutic strategy development), and In Vivo Modeling (high-throughput zebrafish models with machine vision). The platform connects prediction with proof by identifying patterns across millions of data points and validating them in living biological models. The company applies this integrated platform across three therapeutic program areas: Neurology (including KCC2/Epilepsy, Parkinson's Disease, and Alcohol Use Disorder programs), Oncology, and Biodefense. The platform was recently expanded through a $20M acquisition adding blood-brain barrier (BBB) delivery technology including a prodrug system and nose-to-brain delivery pathway to enable CNS therapeutics to reach the brain.

Differentiator

Problem solved

Functional benefit

Products and services

• Augusta AI/ML engine that integrates genomic, proteomic, and phenotypic data into a unified view of disease to identify therapeutic targets and biomarkers. Offered to pharmaceutical partners for drug discovery collaborations.
• Phenograph Translational system that converts raw discovery insights into prioritized therapeutic strategies, ranking targets by druggability, patient stratification, and clinical feasibility. Used in pharmaceutical R&D collaborations.
• In Vivo Modeling High-throughput living-model system combining zebrafish models with AI and machine vision analysis to capture real-time behavior, morphology, and physiology. Delivered to pharma partners for mechanistic and efficacy validation.
• KCC2 (Epilepsy Program) Neurology therapeutic program targeting the KCC2 transporter for epilepsy, integrating behavioral, electrical, and physiological signals to reveal mechanisms and treatment effects. Advanced through R&D collaborations.
• PD (Parkinson's Disease Program) Neurology therapeutic program developing treatments for Parkinson's Disease using Lunai's AI-biology integration platform.
• Alcohol Use Disorder Program Neurology therapeutic program developing treatments for alcohol use disorder using Lunai's platform capabilities.
• Oncology Program Oncology program that uses predictive biomarkers to identify responders with precision, improve patient stratification, and surface resistance mechanisms earlier for immunotherapy and targeted therapy development.
• Biodefense Program Biodefense program that extends platform capabilities to preparedness and global resilience, including real-time neurotoxicity assessment for rapid countermeasures.
• BBB Delivery Platform Blood-brain barrier delivery platform enabling therapeutics to cross the BBB, remain inactive systemically, and activate specifically in the brain, targeting acetylcholinesterase modulation pathways implicated in neurological diseases. Includes a prodrug system and a nose-to-brain delivery pathway.

Quantifiable outcome

• Compresses drug discovery timelines and lowers attrition rates

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core.

• Clemann GroupcoreTechnology or IntegrationLunai acquired blood-brain barrier delivery technology and CNS Alzheimer's drug assets from Clemann Group, SAS for $20 million structured as Series B Convertible Preferred shares. The acquisition provides BBB delivery platform enabling therapeutics to cross the blood-brain barrier and activate specifically in the brain.
• PfizercoreStrategic or Co-development PartnerStrategic R&D collaboration for biomarker discovery and validation. This partnership gives Lunai access to diverse datasets and pipelines while proving technology's readiness for deployment.
• JanssencoreStrategic or Co-development PartnerTarget identification and validation collaboration. Partnership provides access to diverse datasets and validates Lunai's AI-biology integration platform.
• MerckcoreStrategic or Co-development PartnerStrategic R&D collaboration for drug development powered by AI-biology integration. Partnership proves technology readiness for deployment.
• SupernuscoreStrategic or Co-development PartnerNeurology-focused compound development collaboration. Partnership extends Lunai's capabilities in CNS drug development.
• CurecoreStrategic or Co-development PartnerStrategic R&D collaboration providing access to diverse pipelines while proving Lunai's technology readiness for deployment in drug discovery.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Insitro: Insitro uses machine learning on large-scale human cell-derived data to predict drug targets and outcomes. Directly comparable AI-first biotech with pharma partnerships and an internal pipeline targeting metabolic and neurological diseases.
• Schrödinger: Schrödinger provides physics-based computational drug discovery software and collaborates with pharma on targets and molecules. Comparable to Lunai in serving pharma R&D with AI/ML-enabled discovery, though Schrödinger relies more on in silico methods and less on living biological validation.
• Exscientia: Exscientia pioneered AI-designed small molecule drug discovery with pharma collaborations including Bayer, Sanofi, and GSK. Comparable B2B AI-drug-discovery GTM and pre-commercial revenue profile.
• Atomwise: Atomwise applies AtomNet deep learning to small molecule hit discovery, partnering with pharma and pursuing internal programs. Comparable AI discovery vendor with multi-pharma collaborations.
• Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery platform combining high-throughput biology with machine learning, very similar to Lunai's Augusta + zebrafish in vivo loop. Both sell platform partnerships to large pharma and pursue internal pipeline assets.

Emerging players

• Lantern Pharma: Lantern Pharma uses AI to rescue and develop oncology drug candidates with a small-cap public structure. Comparable as a publicly traded AI-drug-discovery peer with oncology focus.
• Denali Therapeutics: Denali Therapeutics is a clinical-stage CNS biotech with proprietary BBB transport vehicle technology for delivering therapeutics across the blood-brain barrier. Closest functional peer to Lunai's newly acquired BBB delivery platform.
• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide therapeutics including CNS-penetrant molecules. Comparable on the BBB-crossing therapeutic delivery angle that Lunai is building around through its Clemann-acquired platform.

Broad incumbents

• Ginkgo Bioworks: Ginkgo Bioworks is a broad synthetic biology platform serving pharma and industrial biotech customers. Comparable in platform-services GTM to pharma but at much larger scale and different application focus.
• Tempus AI: Tempus AI combines multimodal clinical/molecular data with AI for pharma R&D and clinical decision support. Broader incumbent in the AI-pharma services space overlapping Lunai's biomarker and target discovery offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/enochian_biosci
• LinkedInlinkedin.com/company/renovaro-biosciences-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lunai Bioworks